Advance-CTR Pilot Projects Program (2018)
"Modification of Orthopaedic Biomaterials with Osteolysis Inhibitors and Osteoconductive Peptides"
Co-PIs: Douglas Moore, MS, Anita Shukla, PhD, and Wentian Yang, MD, PhD
Despite the success of joint arthroplasty, over 17.5% of hips and 8.2% of knee implants are currently being revised due to complications, usually osteolysis (30-40%). Polyethylene particles or metal debris- trigged local osteoclastogenesis and bone resorption are the primary cause of this scenario. None of current manufacturing approaches attempt to resolve the process of osteolysis and instead are typically limited to mechanical modifications on the surface. We now hypothesize that modifying orthopedic titanium alloy surfaces with osteolysis inhibitors would prevent the osteolytic process and thus improve the survival of implants, potentially preventing costly revision surgery and patient disability.